Trial Profile

KENya Single-dose HPV-vaccine Efficacy - The KEN-SHE Study

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 04 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Human papillomavirus vaccine recombinant bivalent Japan Vaccine/MedImmune (Primary) ; V 503 (Primary) ; Meningococcal vaccine groups A C Y W-135 conjugate
Indications Human papillomavirus infections
Focus Therapeutic Use
Acronyms KEN-SHE

Most Recent Events

28 Jul 2022 Planned End Date changed from 15 Nov 2022 to 15 Feb 2024.
28 Jul 2022 Planned primary completion date changed from 15 Nov 2022 to 15 Feb 2024.
07 Feb 2020 Planned End Date changed from 31 Dec 2021 to 15 Nov 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com